{"brief_title": "Study Evaluating rhIL-11 in Left-Sided Ulcerative Colitis", "brief_summary": "To explore the safety of orally delivered rhIL-11 in patients with mild to moderate left-sided ulcerative colitis. To explore the effects of orally administered rhIL-11 on pharmacogenomics in blood samples and in colonic biopsy tissue samples.", "condition": "Inflammatory Bowel Disease", "intervention_type": "Drug", "intervention_name": "rhIL-11", "criteria": "Inclusion Criteria: - Documented, signed informed consent to participate in this study - Age greater than or equal to 18 years - Documented diagnosis of ulcerative colitis by standard clinical criteria, including endoscopy (either flexible sigmoidoscopy or colonoscopy, sufficient to define the proximal limit of disease) with biopsy Exclusion Criteria: - Crohn's disease - Ulcerative proctitis - Ulcerative colitis extending beyond the splenic flexure", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00038922.xml"}